Screener
ArriVent BioPharma, Inc. AVBP Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $37,617 | $61,289 |
| General and administrative | 8,494 | 5,483 |
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s total operating expenses?
- ArriVent BioPharma, Inc. (AVBP) reported total operating expenses of $46.11M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total operating expenses changed year-over-year?
- ArriVent BioPharma, Inc.'s total operating expenses decreased by 30.9% year-over-year, from $66.77M to $46.11M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total operating expenses?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total operating expenses has grown at a 54.3% compound annual growth rate (CAGR), from $74.59M to $177.53M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about ArriVent BioPharma, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude